Page 150 - Binder2
P. 150
When drugs last, everything else works better.
And when they don’t, the cost isn’t just financial—it’s
structural.
That’s why immune compatibility is more than a scientific
upgrade.
It’s an economic imperative.
One the entire industry can no longer afford to ignore.
What We Gain When Drugs Stay
When we design for immune acceptance:
• Patients stay on therapy longer—and get their
lives back, not just their numbers down
• Payers regain control over runaway costs driven
by biologic churn
• Clinicians can treat with confidence, not
guesswork
• Manufacturers differentiate not just on novelty,
but on durability
And the entire biologics category becomes something it’s
struggling to be right now:
Sustainable.
Not just profitable.
Not just scalable.
But built to endure—scientifically, clinically, and
economically.
Right now, biologics are among the most powerful tools we
have in medicine.
They’re the workhorses of autoimmune care, the backbone
148
